Brief: GeNeuro FY Operating Loss Narrows To 6.4 Million Euros

Geneuro SA

04/04/2022 07:39

April 4 (Reuters) - GENEURO SA  GNRO.PA :
    * FY NET CASH POSITION OF 5.5 MILLION EUROS AS OF DECEMBER
31,
2021, EXCLUDING FOPH PAYMENT, OFFERING GOOD FINANCIAL VISIBILITY
INTO Q2 OF 2023
    * CLINICAL TRIAL OF TEMELIMAB AGAINST NEUROPSYCHIATRIC
SYNDROMES
OF POST-COVID-19: GENEURO RECEIVED IN JANUARY 2022 FIRST
INSTALMENT OF EUR 3 MILLION FROM SWISS FEDERAL OFFICE OF PUBLIC
HEALTH (FOPH)
    * TOP-LINE RESULTS OF PROTECT-MS CLINICAL TRIAL OF TEMELIMAB
IN
MULTIPLE SCLEROSIS (MS): PRIMARY ENDPOINT MET, CONFIRMATION OF
SYNERGISTIC POTENTIAL TO ADDRESS NEURODEGENERATION
    * WITH COMPLETION OF PROTECT-MS TRIAL, GENEURO'S CASH
POSITION AT
YEAR-END 2021 PROVIDES GOOD FINANCIAL VISIBILITY INTO Q2-2023
BASED ON ITS CURRENT ACTIVITIES
    * FY OPERATING LOSS EUR 6.4 MILLION VERSUS LOSS EUR 7.5
MILLION
YEAR AGO
    * PRIORITIES FOR 2022 ARE TO RESUME DISCUSSIONS WITH
REGULATORY
AUTHORITIES AND WITH POTENTIAL PARTNERS TO DEFINE BEST
DEVELOPMENT PATH COMBINING TEMELIMAB AND ANTI-NEUROINFLAMMATORY
TREATMENTS
    * FY NET LOSS EUR 6.8 MILLION VERSUS LOSS EUR 8.9 MILLION
YEAR AGO
    * OUTLOOK: TO FINALIZE ITS PRE-CLINICAL PROGRAM IN ALS,
SEEKING TO
BRING THIS PROJECT TO AN IND BY EARLY 2023
    * OUTLOOK: COMPANY CONTINUES TO SEEK DEDICATED FINANCING TO
LAUNCH
ITS PHASE 2 IN POST-COVID

Source text for Eikon:  ID:nBw9K6FkDa 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))